Verrica Pharmaceuticals Inc. Payments to Acquire Marketable Securities
Verrica Pharmaceuticals Inc. (VRCA) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2024-02-29
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for the quarter ending 2023-06-30 was $0.00.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for fiscal 2022 was $4.49M, a 93.49% decline from fiscal 2021.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for fiscal 2021 was $68.91M, a 3.94% decline from fiscal 2020.
- Verrica Pharmaceuticals Inc. payments to acquire marketable securities for fiscal 2020 was $71.74M, a 20.16% decline from fiscal 2019.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $8.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $8.00K derived: sum of 3 quarters · filed 2024-02-29 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $8.00K derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $4.49M 10-K · filed 2024-02-29 |
| 2022-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $4.49M 10-Q · filed 2023-11-09 | $14.31M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $4.48M 10-Q · filed 2023-08-08 | $14.30M derived: sum of 3 quarters · filed 2023-08-08 | $27.18M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $4.49M 10-Q · filed 2023-05-09 | $14.31M derived: sum of 2 quarters · filed 2023-05-09 | $27.18M derived: sum of 3 quarters · filed 2023-05-09 | $64.11M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $9.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $22.70M derived: sum of 2 quarters · filed 2023-03-06 | $59.63M derived: sum of 3 quarters · filed 2023-03-06 | $68.91M 10-K · filed 2023-03-06 |
| 2021-09-30 | $12.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $49.80M derived: sum of 2 quarters · filed 2022-11-07 | $59.09M 10-Q · filed 2022-11-07 | $71.28M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $36.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $46.22M 10-Q · filed 2022-08-11 | $58.41M derived: sum of 3 quarters · filed 2022-08-11 | $95.82M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $9.29M 10-Q · filed 2022-05-09 | $21.48M derived: sum of 2 quarters · filed 2022-05-09 | $58.89M derived: sum of 3 quarters · filed 2022-05-09 | $75.64M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $12.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $49.60M derived: sum of 2 quarters · filed 2022-03-02 | $66.36M derived: sum of 3 quarters · filed 2022-03-02 | $71.74M 10-K · filed 2022-03-02 |
| 2020-09-30 | $37.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $54.16M derived: sum of 2 quarters · filed 2021-11-12 | $59.55M 10-Q · filed 2021-11-12 | $76.17M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $16.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $22.14M 10-Q · filed 2021-08-10 | $38.76M derived: sum of 3 quarters · filed 2021-08-10 | $62.76M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $5.38M 10-Q · filed 2021-05-07 | $22.00M derived: sum of 2 quarters · filed 2021-05-07 | $46.00M derived: sum of 3 quarters · filed 2021-05-07 | $73.94M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $16.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $40.62M derived: sum of 2 quarters · filed 2021-03-17 | $68.56M derived: sum of 3 quarters · filed 2021-03-17 | $89.85M 10-K · filed 2021-03-17 |
| 2019-09-30 | $24.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $51.94M derived: sum of 2 quarters · filed 2020-11-09 | $73.23M 10-Q · filed 2020-11-09 | $93.73M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $27.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $49.23M 10-Q · filed 2020-08-05 | $69.73M derived: sum of 3 quarters · filed 2020-08-05 | |
| 2019-03-31 | $21.30M 10-Q · filed 2020-05-07 | $41.79M derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $20.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $79.12M 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $58.62M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |